Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

1(17%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 2Efficacy & side effects

6(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Completed(1)

Other(1)

Detailed Status

Not yet recruiting3

Recruiting1

Completed1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 26 (100.0%)

Trials by Status

recruiting117%

completed117%

not_yet_recruiting350%

unknown117%

Recent Activity

1 active trials

Showing 5 of 6

not_yet_recruitingphase_2

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients

NCT06284590

unknownphase_2

L19IL2/L19TNF in Skin Cancer Patients

NCT05329792

View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials

NCT07227350Phase 2

L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)

Not Yet Recruiting

NCT07227870Phase 2

L19IL2/TNF in Patients With Basal Cell Carcinoma

Not Yet Recruiting

NCT07228442Phase 2

L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma

Not Yet Recruiting

NCT06284590Phase 2

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients

Recruiting

NCT05329792Phase 2

L19IL2/L19TNF in Skin Cancer Patients

Unknown

NCT02076633Phase 2

Intratumoral Administration of L19IL2/L19TNF

Completed

All 6 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 6